{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:00:43Z","timestamp":1778832043183,"version":"3.51.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>In-transit cutaneous metastases occur in 5% to 10% of patients with melanoma. Recently, topical diphenylcyclopropenone (DPCP) has been described as a treatment option.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate efficacy of DPCP in treatment of in-transit cutaneous melanoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>The authors retrospectively reviewed the records of 13 consecutive patients with in-transit metastases treated with topical DPCP between March 1, 2013, and January 31, 2017. The authors recorded the response of in-transit cutaneous melanoma lesions treated with DPCP measured by clinical examination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Among the 13 patients, 9 patients completed at least a 1-month course of DPCP treatment. Of these 9 patients, 6 (66.7%) maintained either stable disease or had a partial or complete regression, and 3 (33.3%) had progressive disease. Patients with less burden of disease (e.g., &lt;15 lesions) responded more favorably than those with a greater burden of disease (e.g., &gt;25 lesions or plaques). Both patients who received DPCP alone had progression of their cutaneous lesions. One patient who did not become sensitized to DPCP died within 2 months, and his anergy likely reflecting immense burden of disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Topical DPCP is a low-cost, patient-applied treatment option for in-transit melanoma, most effective for patients with relatively low tumor burden and localized disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000001603","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T09:02:59Z","timestamp":1530954179000},"page":"1501-1508","source":"Crossref","is-referenced-by-count":18,"title":["Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience"],"prefix":"10.1097","volume":"44","author":[{"given":"Kevin K.","family":"Veverka","sequence":"first","affiliation":[{"name":"Mayo Clinic School of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Jakub","sequence":"additional","affiliation":[{"name":"Surgery, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian L.","family":"Baum","sequence":"additional","affiliation":[{"name":"Dermatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene","volume":"41","author":"Cohen","year":"1978","journal-title":"Cancer"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jaad.2006.12.018","article-title":"Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone","volume":"56","author":"Damian","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jso.22029","article-title":"Local and intralesional therapy of in-transit melanoma metastases","volume":"104","author":"Testori","year":"2011","journal-title":"J Surg Oncol"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jso.23506","article-title":"Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma","volume":"109","author":"Damian","year":"2014","journal-title":"J Surg Oncol"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/CJI.0000000000000098","article-title":"Treatment of in-transit melanoma with intralesional Bacillus Calmette-Gu\u00e9rin (BCG) and topical imiquimod 5% cream: a report of 3 cases","volume":"38","author":"Kibbi","year":"2015","journal-title":"J Immunother"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1524-4725.1993.tb00989.x","article-title":"Pooled analysis of the efficacy of Bacillus Calmette-Guerin (BCG) immunotherapy in malignant melanoma","volume":"19","author":"Tan","year":"1993","journal-title":"J Dermatol Surg Oncol"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/CMR.0b013e32831328c7","article-title":"Chemoablation of metastatic melanoma using intralesional Rose Bengal","volume":"18","author":"Thompson","year":"2008","journal-title":"Melanoma Res"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00008390-199712000-00010","article-title":"Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma","volume":"7","author":"Strobbe","year":"1997","journal-title":"Melanoma Res"},{"key":"R11-20230814","first-page":"293","article-title":"Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years)","volume":"4","author":"Illig","year":"1984","journal-title":"Anticancer Res"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00432-006-0182-9","article-title":"Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group","volume":"133","author":"Terheyden","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.14314","article-title":"Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin: the 5-year Norwich experience","volume":"174","author":"Moncrieff","year":"2016","journal-title":"Br J Dermatol"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2017.1286984","article-title":"Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series","volume":"13","author":"Yeung","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(89)90619-3","article-title":"Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine","volume":"2","author":"Harland","year":"1989","journal-title":"Lancet"},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000088512","article-title":"Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma","volume":"211","author":"Trefzer","year":"2005","journal-title":"Dermatology"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/1744666X.2014.850415","article-title":"Immunomodulation of malignant melanoma by contact sensitizing agents","volume":"10","author":"Trowbridge","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"175265","DOI":"10.1155\/2014\/175265","article-title":"Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity","volume":"2014","author":"Erkes","year":"2014","journal-title":"J Immunol Res"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1111\/jdv.14422","article-title":"Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases: results of a prospective, non-randomized, single-centre study","volume":"31","author":"Read","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2133.2001.04399.x","article-title":"The therapeutic use of topical contact sensitizers in benign dermatoses","volume":"145","author":"Buckley","year":"2001","journal-title":"Br J Dermatol"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0733-8635(18)30255-9","article-title":"Topical immunotherapy of alopecia areata","volume":"11","author":"van der Steen","year":"1993","journal-title":"Dermatol Clin"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201812000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:39:36Z","timestamp":1692041976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201812000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001603","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}